Since shareholders/public peons aren't being apprised of regulatory inspections by Teva (another IHubber tried), and they've never mentioned it in public, I asked an analyst who follows Teva if she'd ask. Some suspect there is still BS coming from Teva on this, and it is possible. Some wonder how consequential this is, even if definitely true, as you've seen here. The whole business started here (I post as RockRat on Ihub, in case you haven't noticed)
siliconinvestor.com
and, of course ignited a flurry of analysis (I was a little provocative) on IHub, as you'll see from following replies to the above link. I still don't know if my questions were relayed verbally or textually. I am debating whether or not to ask, since she already did me a little favor for no return, and might possibly have hurt her standing with Teva a smidge (but hey, that was her call; she'd be awfully naive to think the answer would not be made public; I was somewhat surprised to get a result of any kind, as I am not even a client of her company).
Other people have asked analysts with whom they have connections and we'll see what else shakes out. I am hoping this will come up now in Teva's next public presentation.
Cheers, Tuck |
